Learn more about investing in Particella

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
We don’t spam. Our Privacy Policy and Cookie Policy apply. The site is protected by reCAPTCHA.
Particella
Particella
Oral Gene Medicines
INVESTOR INQUIRIES
Biopharma Human Health Therapeutics IBSF05 2017 Seed Human Health 100 United States
* Data source: Crunchbase
Founded
2016
Employees*
2-10
Website
particella.bio
* Data source: Crunchbase

Particella Inc., (formerly DNAlite Therapeutics) is a biotechnology company that has developed a novel proprietary lipid nanoparticle that can deliver mRNA and other nucleic acids orally.

Team
Mubhij Ahmad
CEO & Co-Founder
Timothy Day
CSO & Co-Founder
Company News
global university venturing | August 10, 2018
DNAlite musters $1.5m seed round
Global University Venturing
PE Hub | August 08, 2018
DNAlite Therapeutics fetches $1.5 mln
DNAlite Therapeutics Inc, an gastrointestinal gene therapy biotech startup, has raised $1.5 million in seed financing. Berkeley Catalyst Fund led the round with participation from University of California Berkeley, Blue Bear Ventures, SOSV, the Baldota family, BrightGene and SVE Capital.
businesswire | July 15, 2020
New Partner Arvind Gupta & Genesis Consortium Reflect Mayfield's Commitment to Human and ...
SEE ALL NEWS